We are experiencing extremely high call volume related to COVID-19 vaccine interest. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this web site. Please know that our vaccine supply is extremely small. Read all COVID-19 Vaccine Information.
Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts
Enter the last name, specialty or keyword for your search below.
Research in the Brian Garibaldi Lab focuses on acute lung injury (ALI) resolution. Recently, we evaluated the mechanisms underlying mobility therapy and found that therapeutic exercise reduces neutrophilic lung injury and skeletal muscle wasting in ALI mice.
The Charles Wiener Lab primarily conducts research on pulmonary circulation and hypoxia as well as respiratory muscle function in patients with neuromuscular diseases. Our recent studies have included investigating the treatment of pericardial effusions in patients with pulmonary arterial hypertension and examining the use of non-invasive ventilation in patients with amyotrophic lateral sclerosis (ALS). We also have an interest in medical education research. Our work in this area has included reviewing the role of academic medical centers in emerging health care markets.
Research efforts in the Edward Chen Lab focus on bleomycin-induced pulmonary fibrosis and granulomatous inflammation as well as clinical and translational studies in sarcoidosis. Our studies have included topics such as the etiologies of sarcoidosis, hylleraas hydride binding energy in diatomic electron affinities, and molecular convergence of neurodevelopmental disorders. We have also investigated the use of quantitative mass spectrometric analysis to better understand the mechanisms of phospho-priming and auto-activation of the checkpoint kinase Rad53 in vivo.
Work in the Enid Neptune Lab focuses on topics within the fields of pulmonary and critical care medicine. Our research centers primarily on therapeutic strategies for Marfan syndrome and hepatocyte growth factor signaling in airspace homeostasis. We also conduct research on chronic obstructive pulmonary disease (COPD), with a focus on its mechanisms and potential methods for preventing its progression. Our research within critical care has most recently involved investigating superoxide dismutase 3 dysregulation in neonatal lung injuries.
Research in the Eric McCollum Lab focuses on pediatric pulmonary medicine, particularly pulmonary diseases among children in undeveloped, low-resource countries. We are taking part in the IMPACT trial, which looks at the impact of bubble continuous positive airway pressure (bCPAP) on the mortality of Malawian children with pneumonia.
The Franco D’Alessio Lab investigates key topics within the fields of critical care, internal and pulmonary medicine. We primarily explore immunological determinants of acute lung inflammation and repair. Our lab also investigates age-dependent lung immune response in patients with acute lung injury and acute respiratory distress syndrome (ARDS), regulatory T-cells in lung injury and repair, and modulation of alveolar macrophage innate immune response in ARDS.
Research in the Henry Fessler Lab is focused on pulmonary medicine. We are interested in heart-lung interaction, mechanical ventilation and lung mechanics. We’re also interested in medical education and recently examined contemporary strategies for effective lecturing.
Research in the James Sham Lab focuses on pulmonary arteries. Studies include local calcium signaling in the pulmonary arteries and transient receptor potential (TRP) channels in pulmonary arterial smooth muscle cells. We’re also interested in calcium regulation in chronic hypoxic pulmonary hypertension.
The Jonathan Jun Lab studies the function of lipolysis in intermittent hypoxia-induced insulin resistance.
Research in the Jonathan Orens Lab examines topics such as clinical outcomes of lung transplantation, chronic allograft rejection and ischemic reperfusion injury, also known as primary graft dysfunction.
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
